TR200003443T2 - Geçmeyen depresyonun tedavisi için kombinasyon terapisi - Google Patents

Geçmeyen depresyonun tedavisi için kombinasyon terapisi

Info

Publication number
TR200003443T2
TR200003443T2 TR2000/03443T TR200003443T TR200003443T2 TR 200003443 T2 TR200003443 T2 TR 200003443T2 TR 2000/03443 T TR2000/03443 T TR 2000/03443T TR 200003443 T TR200003443 T TR 200003443T TR 200003443 T2 TR200003443 T2 TR 200003443T2
Authority
TR
Turkey
Prior art keywords
treatment
depression
impressive
combination therapy
activity
Prior art date
Application number
TR2000/03443T
Other languages
English (en)
Turkish (tr)
Inventor
Dennis Tollefson Gary
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200003443T2 publication Critical patent/TR200003443T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Oxide Ceramics (AREA)
TR2000/03443T 1998-05-22 1999-05-21 Geçmeyen depresyonun tedavisi için kombinasyon terapisi TR200003443T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22

Publications (1)

Publication Number Publication Date
TR200003443T2 true TR200003443T2 (tr) 2001-03-21

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03443T TR200003443T2 (tr) 1998-05-22 1999-05-21 Geçmeyen depresyonun tedavisi için kombinasyon terapisi

Country Status (24)

Country Link
EP (1) EP0958824A3 (cg-RX-API-DMAC7.html)
JP (1) JP2002516282A (cg-RX-API-DMAC7.html)
KR (1) KR20010043730A (cg-RX-API-DMAC7.html)
CN (1) CN1154496C (cg-RX-API-DMAC7.html)
AU (1) AU761510B2 (cg-RX-API-DMAC7.html)
BR (1) BR9911049A (cg-RX-API-DMAC7.html)
CA (1) CA2332814C (cg-RX-API-DMAC7.html)
CZ (1) CZ20004279A3 (cg-RX-API-DMAC7.html)
EA (1) EA004539B1 (cg-RX-API-DMAC7.html)
HK (1) HK1040055B (cg-RX-API-DMAC7.html)
HR (1) HRP20000797A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0101901A3 (cg-RX-API-DMAC7.html)
ID (1) ID26861A (cg-RX-API-DMAC7.html)
IL (1) IL139592A (cg-RX-API-DMAC7.html)
MY (1) MY127938A (cg-RX-API-DMAC7.html)
NO (1) NO20005885L (cg-RX-API-DMAC7.html)
NZ (1) NZ507980A (cg-RX-API-DMAC7.html)
PL (1) PL344331A1 (cg-RX-API-DMAC7.html)
SK (1) SK17512000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200003443T2 (cg-RX-API-DMAC7.html)
TW (1) TWI226829B (cg-RX-API-DMAC7.html)
UA (1) UA78181C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999061027A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200006815B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352611A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
MXPA06002504A (es) * 2003-09-04 2006-06-20 Lundbeck & Co As H Combinacion de un inhibidor de recaptacion de serotonina y loxapina.
SG146683A1 (en) 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005056056A2 (en) * 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2275096A3 (en) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H 4-〔2-(4-甲基苯硫基)苯基〕哌啶之新穎治療用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法
ES3054324B2 (es) * 2024-07-12 2026-08-10 Univ De Malaga Galanina (1-15) y Fluoxetina en el tratamiento de la depresión resistente al tratamiento

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1997033577A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
IL139592A (en) 2005-08-31
ID26861A (id) 2001-02-15
WO1999061027A1 (en) 1999-12-02
CN1154496C (zh) 2004-06-23
HUP0101901A2 (hu) 2001-11-28
KR20010043730A (ko) 2001-05-25
JP2002516282A (ja) 2002-06-04
SK17512000A3 (sk) 2002-02-05
AU4008699A (en) 1999-12-13
CZ20004279A3 (cs) 2001-09-12
NZ507980A (en) 2003-10-31
AU761510B2 (en) 2003-06-05
PL344331A1 (en) 2001-11-05
HUP0101901A3 (en) 2002-06-28
CN1311681A (zh) 2001-09-05
HK1040055B (zh) 2005-04-01
NO20005885L (no) 2001-01-17
NO20005885D0 (no) 2000-11-21
HRP20000797A2 (en) 2001-10-31
MY127938A (en) 2007-01-31
CA2332814C (en) 2008-11-04
EP0958824A3 (en) 1999-12-01
HK1040055A1 (en) 2002-05-24
IL139592A0 (en) 2002-02-10
UA78181C2 (en) 2007-03-15
EA200001218A1 (ru) 2001-06-25
TWI226829B (en) 2005-01-21
EP0958824A2 (en) 1999-11-24
ZA200006815B (en) 2002-01-14
CA2332814A1 (en) 1999-12-02
BR9911049A (pt) 2001-02-06
EA004539B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
MY127938A (en) Combinatin therapy for treatment of partial responders or refractory depression
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
EA199800667A1 (ru) Новые фенантридины
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DK1558616T4 (da) Meso-substituerede porphyriner
EP1068870A4 (en) ANTITUMORAL AGENTS
PT1742644E (pt) Composição terapêutica que contém pelo menos um derivado de pirrolobenzodiazepina e fludarabina
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
TR200003159T2 (tr) Antipicornaviral bileşikler, hazırlanışları ve kullanımları
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
ATE332708T1 (de) Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
NO994330L (no) Metode for behandling av en tumor
NO20055002L (no) Benzol[1,2,5]tiadiazolforbindelser
BR0009194A (pt) Composição do resorcinol
ATE418613T1 (de) Antimikrobielle zusammensetzungen
EA200300572A1 (ru) Комбинированная терапия эстроген-зависимых заболеваний
DE60143681D1 (de) Kombinationstherapie gegen Tumoren mit substituierten Acryloyl-Distamycin-Derivaten, Taxanen und/oder Antimetaboliten
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE60318561D1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
RU94024337A (ru) Антиметастатическое средство
EA200200321A1 (ru) Апоптин-ассоциированный белок
ES2170479T3 (es) Agente viral terapeutico que detiene el desarrollo de tumores.